Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,413 | -7,992 | -5,591 | -2,827 | -98,298 |
| Depreciation Amortization | 7 | 7 | 5 | 3 | 11,905 |
| Income taxes - deferred | 7 | 10 | 10 | N/A | -9,479 |
| Accounts payable and accrued liabilities | 889 | 676 | -115 | -304 | 2,406 |
| Other Working Capital | 970 | 1,038 | -586 | -1,263 | 2,600 |
| Other Operating Activity | 22 | -44 | 586 | 614 | 82,145 |
| Operating Cash Flow | $-7,520 | $-6,305 | $-5,691 | $-3,777 | $-8,721 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 6,541 | 3,501 | 2,673 | 2,673 | 19,082 |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -7 |
| Other Financing Activity | -628 | -210 | 0 | 0 | -13,118 |
| Financing Cash Flow | $5,913 | $3,290 | $2,673 | $2,673 | $5,956 |
| Beginning Cash Position | 3,138 | 3,138 | 3,138 | 3,138 | 5,902 |
| End Cash Position | 1,531 | 123 | 120 | 2,034 | 3,138 |
| Net Cash Flow | $-1,607 | $-3,015 | $-3,018 | $-1,104 | $-2,765 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,520 | -6,305 | -5,691 | -3,777 | -8,721 |
| Free Cash Flow | -7,520 | -6,305 | -5,691 | -3,777 | -8,721 |